#1 Clinical Trials Search in Europe

Istradefylline

Istradefylline, also known as KW-6002, is a drug being studied in clinical trials for the treatment of Parkinson’s disease. This article explores the use of istradefylline in various clinical trials, focusing on its potential benefits for reducing “off” time, improving motor symptoms, and addressing cognitive impairment in Parkinson’s disease patients.

Table of Contents

What is Istradefylline?

Istradefylline, also known by its brand name Nourianz or research code KW-6002, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson’s disease[1]. It is used as an add-on therapy for patients who are already taking levodopa, the primary medication used to manage Parkinson’s symptoms[2].

How Does It Work?

Istradefylline works differently from other Parkinson’s medications. It targets specific receptors in the brain called adenosine A2A receptors. By blocking these receptors, istradefylline helps to improve the effectiveness of levodopa and reduce the “off” time that patients experience[3]. “Off” time refers to periods when Parkinson’s symptoms return as the effect of levodopa wears off.

What Conditions Does It Treat?

Istradefylline is primarily used to treat Parkinson’s disease, specifically in patients who experience motor fluctuations while on levodopa therapy. These motor fluctuations include:

  • Off episodes: Periods when Parkinson’s symptoms (such as tremor, stiffness, and difficulty moving) return as the effect of levodopa wears off[2].
  • Dyskinesia: Uncontrolled, involuntary movements that can occur as a side effect of long-term levodopa use[1].

Additionally, there is ongoing research to explore the potential benefits of istradefylline in treating cognitive impairment associated with Parkinson’s disease[1].

Dosage and Administration

Istradefylline is typically taken orally once daily. The usual dosing regimen includes:

  • Starting dose: 20 mg per day for 2 weeks[3]
  • Maintenance dose: 40 mg per day[3]

It’s important to note that istradefylline is used as an add-on therapy to levodopa and is not meant to replace other Parkinson’s medications[2].

Effectiveness

Clinical trials have shown that istradefylline can help reduce “off” time in Parkinson’s patients. Specifically, it has been found to:

  • Reduce the total hours of awake time spent in the “off” state[2]
  • Increase “on” time (periods when Parkinson’s symptoms are well-controlled)[1]
  • Improve motor function, as measured by standard Parkinson’s disease rating scales[2]

Side Effects and Safety

Like all medications, istradefylline can cause side effects. Common side effects may include:

  • Dyskinesia (involuntary movements)
  • Dizziness
  • Constipation
  • Nausea
  • Hallucinations

Long-term safety studies have been conducted to evaluate the tolerability of istradefylline over extended periods[4]. It’s important to discuss any side effects with your healthcare provider.

Ongoing Research

Researchers continue to study istradefylline to better understand its effects and potential uses. Current areas of investigation include:

  • Cognitive impairment: A study is underway to determine if istradefylline can improve cognitive function in Parkinson’s patients with mild cognitive impairment[1].
  • Tremor: Researchers are investigating the specific effects of istradefylline on Parkinson’s-related tremor[3].
  • Long-term effects: Ongoing studies are evaluating the long-term safety and efficacy of istradefylline in Parkinson’s disease management[4].

As research continues, our understanding of istradefylline and its potential benefits for Parkinson’s disease patients may expand further.

Aspect Details
Drug Name Istradefylline (KW-6002)
Primary Use Treatment of Parkinson’s disease as an add-on to levodopa
Main Mechanism Targets adenosine A2A receptors in the basal ganglia
Dosages Studied 20 mg and 40 mg daily
Primary Outcomes Reduction in “off” time, increase in “on” time
Secondary Outcomes Improvement in motor symptoms, cognitive function, quality of life
Safety Studies Long-term safety and tolerability assessments
Special Populations Studies in patients with mild hepatic impairment
Cognitive Effects Ongoing research on potential benefits for cognitive impairment
Assessment Tools MDS-UPDRS, Hauser diaries, cognitive tests, quality of life measures

FAQ

  • What is istradefylline and how does it work? Istradefylline is a drug that targets adenosine A2A receptors in the brain. It works by inhibiting the indirect pathway in the basal ganglia, which helps improve motor function in Parkinson's disease patients. It is used as an add-on treatment to levodopa to reduce 'off' time and increase 'on' time.
  • What are the main goals of istradefylline clinical trials? The main goals of istradefylline clinical trials are to evaluate its efficacy in reducing 'off' time, improving motor symptoms, assessing its long-term safety, and investigating its potential benefits for cognitive impairment in Parkinson's disease patients.
  • What doses of istradefylline are being studied? Most clinical trials are studying doses of 20 mg and 40 mg of istradefylline taken orally once daily. Some studies start patients on 20 mg for a few weeks before increasing to 40 mg.
  • What are 'on' and 'off' states in Parkinson's disease? In Parkinson's disease, 'on' time refers to periods when medication (usually levodopa) is working effectively and symptoms are well-controlled. 'Off' time refers to periods when medication wears off and symptoms return or worsen. Istradefylline aims to increase 'on' time and reduce 'off' time.
  • Are there any studies looking at istradefylline for cognitive impairment in Parkinson's disease? Yes, there is a clinical trial (NCT05333549) specifically investigating whether istradefylline can improve cognition in individuals with Parkinson's disease who have cognitive impairment. This study is assessing various aspects of cognitive function, including executive function, memory, and verbal fluency.

Ongoing Clinical Trials on Istradefylline

  • Study on Istradefylline for Reducing Brain Inflammation in Patients with Progressive Multiple Sclerosis

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Finland

Glossary

  • Istradefylline: A drug that targets adenosine A2A receptors in the brain, used as an add-on treatment to levodopa for Parkinson's disease to reduce 'off' time and increase 'on' time.
  • Levodopa: The main medication used to treat Parkinson's disease symptoms by increasing dopamine levels in the brain.
  • Off time: Periods when Parkinson's disease symptoms return or worsen as medication (usually levodopa) wears off.
  • On time: Periods when Parkinson's disease symptoms are well-controlled due to effective medication action.
  • Dyskinesia: Involuntary, uncontrolled movements that can occur as a side effect of long-term levodopa treatment in Parkinson's disease.
  • MDS-UPDRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale, a comprehensive assessment tool used to evaluate the severity of Parkinson's disease symptoms.
  • Cognitive impairment: Difficulties with thinking, memory, and other mental processes that can occur in some people with Parkinson's disease.
  • Executive function: Higher-level cognitive skills that help with planning, organizing, and completing tasks.
  • Basal ganglia: A group of structures in the brain involved in movement control, which are affected in Parkinson's disease.
  • Adenosine A2A receptors: Specific protein molecules in the brain that istradefylline targets to improve motor function in Parkinson's disease.

References

  1. https://clinicaltrials.gov/study/NCT05333549
  2. https://clinicaltrials.gov/study/NCT00955526
  3. https://clinicaltrials.gov/study/NCT05885360
  4. https://clinicaltrials.gov/study/NCT00957203